- Previous Close
891.15 - Open
949.65 - Bid --
- Ask --
- Day's Range
899.20 - 949.65 - 52 Week Range
855.10 - 1,324.30 - Volume
4,159,310 - Avg. Volume
1,282,122 - Market Cap (intraday)
907.627B - Beta (5Y Monthly) 0.56
- PE Ratio (TTM)
20.04 - EPS (TTM)
45.00 - Earnings Date Apr 3, 2025 - Apr 7, 2025
- Forward Dividend & Yield 3.00 (0.34%)
- Ex-Dividend Date Jul 26, 2024
- 1y Target Est
1,063.68
Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally. It operates through two segments: Pharmaceuticals and Consumer Products. It offers finished dosage human formulations, such as generics; branded generics; specialty formulations, including biosimilars and vaccines; active pharmaceutical ingredients; consumer wellness products; animal healthcare products; and products in the therapeutic areas of pain management, neurology, metabolic disorder, and liver diseases. The company provides the products under the Everyuth, Nutralite, SugarFree, Complan, Glucon-D, and Nycil brands. In addition, the company offers a pipeline of biological products in the areas of oncology, autoimmune disease, nephrology, inflammation, rheumatology, hepatology, and infectious illnesses. Further, it engages in the investment, animal health and veterinary, pharmacy retail, and manpower supply and administration activities. The company was formerly known as Cadila Healthcare Limited and changed its name to Zydus Lifesciences Limited in February 2022. Zydus Lifesciences Limited was founded in 1952 and is headquartered in Ahmedabad, India. Zydus Lifesciences Limited is a subsidiary of Zydus Family Trust.
zyduslife.com26,921
Full Time Employees
March 31
Fiscal Year Ends
Sector
Recent News: ZYDUSLIFE.NS
View MorePerformance Overview: ZYDUSLIFE.NS
Trailing total returns as of 4/3/2025, which may include dividends or other distributions. Benchmark is S&P BSE SENSEX (^BSESN) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ZYDUSLIFE.NS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ZYDUSLIFE.NS
View MoreValuation Measures
Market Cap
896.81B
Enterprise Value
868.76B
Trailing P/E
19.80
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
4.15
Price/Book (mrq)
4.11
Enterprise Value/Revenue
4.01
Enterprise Value/EBITDA
12.64
Financial Highlights
Profitability and Income Statement
Profit Margin
20.39%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
222.47B
Net Income Avi to Common (ttm)
45.34B
Diluted EPS (ttm)
45.00
Balance Sheet and Cash Flow
Total Cash (mrq)
24.95B
Total Debt/Equity (mrq)
0.79%
Levered Free Cash Flow (ttm)
--